Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer.

Geburtshilfe Frauenheilkd 2019 Mar 12;79(3):256-267. Epub 2019 Mar 12.

Oncology Practice at Bethanien Hospital Frankfurt, Frankfurt, Germany.

For many years, small but significant advancements have been made time and again in the prevention and treatment of early breast cancer. The so-called panel gene analyses are becoming more and more important in prevention, since the risk due to the tested genes is better understood and as a result, concepts for integration in health care can be developed. In the adjuvant situation, the first study in the so-called post-neoadjuvant situation was able to demonstrate a clear improvement in the prognosis with an absent pathological complete remission following trastuzumab or pertuzumab + trastuzumab. Additional studies with this post-neoadjuvant therapeutic concept are still being conducted at present. The CDK4/6 inhibitors which had shown a significant improvement in progression-free survival in a metastatic situation are currently being tested in the adjuvant situation in large therapeutic studies. These and other new data for the treatment or prevention of primary breast cancer are presented in this review against the backdrop of current studies.

Download full-text PDF

Source
http://dx.doi.org/10.1055/a-0842-6614DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6414304PMC
March 2019
7 Reads

Publication Analysis

Top Keywords

breast cancer
16
early breast
8
adjuvant situation
8
prognosis absent
4
absent pathological
4
improvement prognosis
4
clear improvement
4
demonstrate clear
4
pathological complete
4
complete remission
4
additional studies
4
studies post-neoadjuvant
4
pertuzumab + trastuzumab additional
4
trastuzumab pertuzumab + trastuzumab
4
remission trastuzumab
4
situation demonstrate
4
post-neoadjuvant situation
4
integration health
4
health care
4
concepts integration
4

Similar Publications